For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Astellas Plans to Tap 300 Workers in Japan for Early Retirement in FY2014
November 5, 2013
- Astellas 1st Half Operating Profit Down 4.4% on Higher Sales
November 5, 2013
- Shionogi Logs Record Profits in April-September on Rigid Cost Control
November 1, 2013
- Daiichi Sankyo Sales Up 7% Thanks to Nexium, Ranbaxy Posts Net Loss
November 1, 2013
- Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
- MTPC Sales of Domestic Ethical Drugs Down 3.2% in April-September Period Due to Generic Competition
October 31, 2013
- DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
October 31, 2013
- Stock-Out of Mucosolate, Lemalc Due to Non-Conformance Results of Dissolution Testing, Stable Supply to Resume Next Spring: Teva Pharma Japan
October 31, 2013
- Teva Pharma Japan Notifies Customers of Stock-Out of Mucosolate L Cap.45, Lemalc Tab. 100 Due to Manufacturing Troubles
October 30, 2013
- Taiwan Approval Sought for DSP’s Antipsychotic Lurasidone
October 30, 2013
- Eli Lilly Italy Pres. Jönsson to Take Reins of Japan Operations
October 29, 2013
- Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
- Tamiflu Supply Plan for This Season Down by 3 Million Treatment Courses against Last Season: Chugai
October 25, 2013
- Race for Top Brands for BPH Tightens as Generics Make Inroads; OAB Market Grows as Disease Entity Becomes Better Defined
October 25, 2013
- Ono Licenses Pheochromocytoma Treatment Metyrosine from Valeant
October 24, 2013
- Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
- Shionogi, Nipro to Copromote Anti-Influenza Treatment Rapiacta
October 23, 2013
- Roche Still Tops in Patent Asset Ranking in Japan, Shionogi, MTPC Jumps to Second, Third Place
October 22, 2013
- Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
- BMKK, Pfizer to Change Distribution Channel to Wholesalers for Eliquis, Remain as Copromoters
October 21, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…